← boardnext 2028-01
CRMD
CorMedixdistress 2/10 · well-funded / low risk$7.80-2%today-47% from 52w high
Lead: Central Line Associated Blood Stream Infections (CLABSI)
Revenue
$127M
Liquidity
$178M
Runway
—
Shares 1y
+5%
Price & events
+4.8% over 6M
CatalystRating changeDilutionFinancingdashed = today
-1.8%
1D
-5.9%
1W
-9.3%
1M
+6.4%
3M
+7.3%
6M
-32.9%
1Y
+61.5%
2Y
+27.0%
5Y
+5.7%
All
Overview
- Market Cap
- $611.96M
- Volume
- 31.55K
- 52 Week Range
- $6.25 – $14.83
- Total Shares
- 78.45M
- Float Shares
- 66.53M
- Short %
- 19.29%
- % Held by Insiders
- 7.53%
- % Held by Institutions
- 54.73%
- RVOL
- 0.02x
- Beta
- 1.48
Pipeline stages · 1 programs
(taurolidine and heparin) catheter lock solution, Heparin
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Pipeline · 1 trials · 1 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| 2028-01 Estimated 50% readout ~2028-03-16 | Phase 3 | (taurolidine and heparin) catheter lock solution, Heparin | Central Line Associated Blood Stream Infections (CLABSI) | — | recruiting |
Catalyst news & presentations · 10
- 1H 2027Guided 55%readoutDefenCath · Data for DefenCath in TPN indication expected in first half of 2027.SEC 8-K
- early 2027Guided 70%enrollment completesecondaryPhase 3DefenCath · Phase 3 study of taurolidine/heparin catheter lock solution in TPN patients targeted completionSEC 8-K
- 2H26Guided 55%regulatory submissionFiled (NDA/BLA)REZZAYO · Target sNDA submission to FDA for expanded prophylaxis indication.SEC 8-K
- 2026-08-06Estimated 45%earningsEarningsEarnings releaseyahoo
- Q2 2026readoutPhase 3REZZAYO · Phase 3 ReSPECT study data expectedSEC 8-K
- in 2025trial initiationsecondaryDefenCath · Commencing clinical studies in TPN and pediatric populationsSEC 8-K
- 2025-08-29partnershipCompleted merger with Melinta Therapeutics LLCSEC 8-K
- 2025-08-07partnershipMerger agreement to acquire Melinta TherapeuticsSEC 8-K
- 2025-06-23partnershipDefenCath · Amended LDO agreement to reflect increased useSEC 8-K
- 2025-06-23enrollment delayDefenCath · Increased Q2 net sales guidance from $31M to $35-40MSEC 8-K
Approved drugs (1)
- DEFENCATHHEPARIN SODIUM2023 · Prescription
Capital structure — dilution & financing
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
buy · target $15 (+92% upside) · 5 analysts
- 2026-07-07RBC CapitalOutperform
- 2026-04-28RBC CapitalOutperform
- 2026-04-28CitizensMarket Outperform
- 2026-04-28Leerink PartnersOutperform
- 2026-04-27NeedhamBuy
- 2026-04-27D. Boral CapitalBuy
Competitors — Central Line Associated Blood Stream Infections (CLABSI)
- none identified
Recent news
- 2026-07-20CorMedix (NASDAQ:CRMD) Stock Price Down 5.9% - Time to Sell? - MarketBeat
- 2026-07-20CorMedix Inc (NASDAQ:CRMD) Receives Average Rating of "Moderate Buy" from Analysts - MarketBeat
- 2026-07-18CorMedix Inc. (CRMD) Advances 1.57% as Stock Approaches Key Resistance at $8.84 - Money Flow - dars.gov.et
- 2026-07-14CRMD Stock Jumps As Antifungal Drug Clears Key Trial For $2B Preventive Market - Stocktwits
- 2026-07-13Enterprise value to revenue forward of CorMedix Inc. – NASDAQ:CRMD - TradingView
- 2026-07-13(CRMD) Movement as an Input in Quant Signal Sets - Stock Traders Daily
- 2026-07-09Private Advisor Group LLC Buys 126,131 Shares of CorMedix Inc $CRMD - MarketBeat
- 2026-07-07RBC Capital Maintains CorMedix(CRMD.US) With Buy Rating, Cuts Target Price to $13 - Moomoo
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.